Paradigm Biopharmaceuticals Limited (PBIGF)
OTCMKTS · Delayed Price · Currency is USD
0.2300
0.00 (0.00%)
At close: Feb 10, 2026

PBIGF Balance Sheet

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Equivalents
16.8217.8256.3339.6771.03
Short-Term Investments
-0.050.050.050.05
Cash & Short-Term Investments
16.8217.8756.3839.7271.08
Cash Growth
-5.87%-68.31%41.94%-44.12%-32.09%
Accounts Receivable
----0.02
Other Receivables
6.376.076.816.728.49
Receivables
6.376.076.816.728.51
Prepaid Expenses
0.941.30.60.731.39
Total Current Assets
24.1325.2463.7947.1780.98
Property, Plant & Equipment
0.030.190.340.570.76
Other Intangible Assets
0.412.952.952.952.95
Other Long-Term Assets
----0.1
Total Assets
24.5728.3767.0750.6984.79
Accounts Payable
2.732.8212.167.094.99
Accrued Expenses
0.490.420.780.590.67
Current Portion of Leases
0.010.120.10.150.13
Total Current Liabilities
3.233.3613.047.835.79
Long-Term Leases
-0.120.240.470.62
Pension & Post-Retirement Benefits
---0.08-
Other Long-Term Liabilities
0.150.110.11-0.11
Total Liabilities
3.393.5813.398.386.52
Common Stock
253.23238.11209.83147.19146.99
Retained Earnings
-235.95-219.75-163.51-114.02-75.23
Comprehensive Income & Other
3.96.427.369.136.51
Shareholders' Equity
21.1824.7953.6842.3178.27
Total Liabilities & Equity
24.5728.3767.0750.6984.79
Total Debt
0.010.240.340.620.75
Net Cash (Debt)
16.8117.6356.0439.170.33
Net Cash Growth
-4.62%-68.54%43.30%-44.40%-32.22%
Net Cash Per Share
0.050.060.220.170.31
Filing Date Shares Outstanding
397.43350.36281.76234.25229.91
Total Common Shares Outstanding
389.43350.36281.76232.68229.91
Working Capital
20.8921.8850.7439.3475.18
Book Value Per Share
0.050.070.190.180.34
Tangible Book Value
20.7721.8450.7339.3775.33
Tangible Book Value Per Share
0.050.060.180.170.33
Machinery
0.190.190.190.190.19
Leasehold Improvements
0.020.020.020.020.02
Source: S&P Global Market Intelligence. Standard template. Financial Sources.